Evaluation of intravitreal injection of Rituximab for intraocular lymphoma

Evaluation of intravitreal injection of Rituximab for intraocular lymphoma - Evaluation of intravitreal injection of Rituximab for intraocular lymphoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005604

Enrollment

Registered

2011-05-15

Start date

2008-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intraocular lymphoma

Interventions

Intravitreal injection of Rituximab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients had a history of biopsy-proven CD20-positive intraocular lymphoma that had been treated with repeated intravitreal injection of methotrexate; however, all patients discontinued treatment because of severe corneal epitheliopathy.

Exclusion criteria

Exclusion criteria: The patients who has history of myocardial infarction and brain infarction.

Design outcomes

Primary

Measure	Time frame
best-corrected visual acuity, intraocular pressure, indirect ophthalmoscopy, and slit-lamp examination before and after every treatment	—

Secondary

Measure	Time frame
We also evaluated whether prophylactic treatment of systemic chemotherapy such as high-dose methotrexate (HD-MTX) and intrathecal MTX (IT-MTX) or topical ocular treatments such as intravitreal injections of MTX and rituximab inhibited the onset of CNS involvement in patients with PVRL without cerebral involvement.	—

Countries

Japan

Contacts

Public ContactNoriyasu Hashida

Osaka University Graduate School of Medicine Department of Ophthalmology

nhashida@ophthal.med.osaka-u.ac.jp06-6879-3456

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026